GlassScriptPhysician profile
Marc Hines
NPI 1508211046
$1,400.77
in general payments reported to CMS, 2019-2025
15 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.90 · 2023: $352 · 2024: $608 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292 · Education: $58.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.71 |
| Education | $58.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $550.75 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $147.32 | 2023-2025 | Entyvio, Fosrenol, Eohilia |
| Ardelyx, INC. | $104.22 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $93.63 | 2023-2024 | Dupixent |
| Janssen Biotech, INC. | $92.32 | 2024-2025 | Tremfya, Stelara, Simponi |
| Celltrion USA INC. | $81.63 | 2024-2025 | Zymfentra, Vegzelma |
| Pfizer INC. | $71.24 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $66.41 | 2023-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $41.07 | 2024 | Voquezna |
| Celgene Corporation | $34.82 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.56 | 2022 | |
| Tersera Therapeutics LLC | $33.47 | 2023 | Xermelo |
| Intercept Pharmaceuticals, INC. | $20.44 | 2024 | |
| Ironwood Pharmaceuticals, INC | $15.25 | 2024 | |
| Boston Scientific Corporation | $13.64 | 2025 | Accolade Sr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Hines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.